SCHEMBL5777042

SCHEMBL5777042

Nc1ccc(-c2cnco2)cc1I

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 1/20 0.56
CYP11B1 P15538 1/20 0.51
CYP11B2 P19099 1/20 0.51
NOTUM Q6P988 1/20 0.49
GAA P10253 1/20 0.49
LMNA P02545 1/20 0.49
PKM P14618 1/20 0.49
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
PTK2 Q05397 1/20 0.47
KEAP1 Q14145 1/20 0.45
AAK1 Q2M2I8 5/20 0.43
LTA4H P09960 1/20 0.41
CYP3A4 P08684 2/20 0.40
CYP2D6 P10635 2/20 0.40
PDK2 Q15119 1/20 0.39
IMPDH2 P12268 1/20 0.39
IMPDH1 P20839 1/20 0.39
APP P05067 1/20 0.38
PSEN1 P49768 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29458793 0.84 MAP4K4 (0.61) MAP4K4CYP11B1CYP11B2NOTUMGAA
SCHEMBL24309122 0.84 MAP4K4 (0.61) MAP4K4CYP11B1CYP11B2NOTUMGAA
SCHEMBL17493756 0.79 GAA (0.58) MAP4K4CYP11B1CYP11B2NOTUMGAA
SCHEMBL30292019 0.79 LMNA (0.58) MAP4K4CYP11B1CYP11B2NOTUMGAA
SCHEMBL22170248 0.79 LMNA (0.58) MAP4K4CYP11B1CYP11B2NOTUMGAA
SCHEMBL1450203 0.79 NOTUM (0.58) MAP4K4CYP11B1CYP11B2NOTUMGAA
SCHEMBL14561709 0.79 NOTUM (0.53) MAP4K4CYP11B1CYP11B2NOTUMGAA
SCHEMBL5776255 0.79 CYP11B1 (0.47) MAP4K4CYP11B1CYP11B2NOTUMGAA
SCHEMBL3466581 0.76 LMNA (0.58) MAP4K4CYP11B1CYP11B2NOTUMGAA
SCHEMBL31421202 0.76 GAA (0.53) MAP4K4CYP11B1CYP11B2NOTUMGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060276433-A1 Hydrazone derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-12-07 US disclosed
EP-1612204-A1 HYDRAZONE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276433-A1 Hydrazone derivative APP, PRNP, HTT MAP4K4 4009/4885CYP11B1 604/4885CYP11B2 800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.